The high capital cost of autologous CAR-T manufacturing creates a moat for incumbents like Legend. Consequently, future investment will likely flow towards next-generation platforms like in vivo CAR-T, which promises an "off-the-shelf" solution that eliminates complex external manufacturing and patient pre-conditioning.
Legend, a smaller biotech, partnered with J&J, the leader in multiple myeloma. This symbiotic relationship allowed Legend to focus on its scientific and manufacturing strengths while leveraging J&J's massive commercial scale and deep market expertise to achieve global reach and market leadership.
Legend Biotech committed massive capital to build its world-class cell therapy manufacturing network *after* gaining high conviction from its clinical data. This data-first approach de-risked the decision to invest heavily, ensuring that manufacturing capacity was built for a product with a high probability of success.
To avoid bureaucratic slowdowns as it scales, Legend Biotech maintains its nimble "startup" culture by constantly focusing the team on patient needs. This patient-centricity, combined with efficient leadership decision-making, ensures the company operates with speed and purpose despite its large size.
The next wave of cell therapy, in vivo CAR-T, aims to turn the patient's body into the manufacturing plant. This eliminates the need for apheresis, external manufacturing, and lymphodepletion, effectively creating an off-the-shelf biologic that can be administered in community practices with no wait time.
Legend's R&D model leverages early-stage, investigator-led trials in China to generate clinical data rapidly. This approach allows the company to make quicker, more informed decisions about which programs to advance into larger, global development, creating a more efficient and data-driven pipeline.
To scale autologous CAR-T therapies, Legend Biotech is pursuing a three-part strategy: increasing the number of authorized centers, enabling community and regional hospitals (not just academic hubs) to administer treatment, and promoting outpatient administration to reduce the burden on hospital beds.
